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Abstract
Background: There is a demand for serum markers for the routine assessment of the progression of liver cancer.
We previously found that serum N-linked sugar chains are altered in hepatocellular carcinoma (HCC). Here, we
studied glycomic alterations during development of HCC in a rat model.
Results: Rat HCC was induced by the hepatocarcinogen, diethylnitrosamine (DENA). N-glycans were profiled using
the DSA-FACE technique developed in our laboratory.
In comparison with control rats, DENA rats showed a gradual but significant increase in two glycans (R5a and R5b)
in serum total N-glycans during progression of liver cirrhosis and cancer, and a decrease in a biantennary glycan
(P5). The log of the ratio of R5a to P1 (NGA2F) and R5b to P1 [log(R5a/P1) and log(R5b/P1)] were significantly (p <
0.0001) elevated in HCC rats, but not in rats with cirrhosis or fibrosis or in control rats. We thus propose a GlycoT-
est model using the above-mentioned serum glycan markers to monitor the progression of cirrhosis and HCC in
the DENA-treated rat model. When DENA-treated rats were subsequently treated with farnesylthiosalicyclic acid, an
anticancer drug, progression to HCC was prevented and GlycoTest markers (P5, R5a and R5b) reverted towards
non-DENA levels, and the HCC-specific markers, log(R5a/P1) and log(R5b/P1), normalized completely. Conclusions:
We found an increase in core-a-1,6-fucosylated glycoproteins in serum and liver of rats with HCC, which demon-
strates that fucosylation is altered during progression of HCC. Our GlycoTest model can be used to monitor pro-
gression of HCC and to follow up treatment of liver tumors in the DENA rat. This GlycoTest model is particularly
important because a rapid non-invasive diagnostic procedure for tumour progression in this rat model would
greatly facilitate the search for anticancer drugs.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer and the third leading cause of cancer-
related death in the world [1]. Infection with hepatitis B
virus (HBV) or hepatitis C virus (HCV) is the major
etiologic factor for HCC [2]. A strong correlation exists
between cirrhosis and hepatocarcinogenesis, and most
patients with HCC have pre-existing cirrhosis. Chronic
hepatitis virus infection commonly leads to fibrosis fol-
lowed by cirrhosis and finally hepatocellular carcinoma.
The diagnosis and certainly the follow-up of liver dis-
eases such as cirrhosis and HCC remains a heavily
debated problem [3-6]. Alpha-fetoprotein (AFP) is com-
monly used as a serum biomarker, but its level is nor-
mal in one-third of HCC patients [7,8]. The gold
standard for diagnosis of HCC is histopathological
examination of liver biopsy. Thus, a sensitive and speci-
fic non-invasive serological marker is needed for the
early diagnosis of HCC and for monitoring its
treatment.
Abnormal protein glycosylation is associated with
malignant transformation of cells. The N-linked sugar
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chains are altered in various tumors, and certain glycan
structures are well-known markers of tumor progression
[9-12]. Most serum N-linked glycoproteins are synthe-
sized by the liver or by B-lymphocytes, and any changes
in serum total N-glycans could reflect an alteration of
liver or B-lymphocyte physiology. Thus, changes in the
quantity and type of N-glycans in serum could be uti-
lized for the non-invasive diagnosis of liver diseases.
We and others have reported that N-glycan profiles
generated by DSA-FACE (DNA Sequencer Assisted -
Fluorophore Assisted Carbohydrate Electrophoresis)
could be used as a non-invasive marker for HCV-related
liver cirrhosis [13,14], HBV-related fibrosis [15], and
HBV-related HCC [16,17]. Our previous study also
showed that combining serum N-glycan markers with
AFP improves the efficacy of diagnosing HBV-related
HCC [18].
Investigations of hepatocarcinogenesis make use of
animal models. HCC can be induced in laboratory
animals by various chemicals, such as aflatoxin B1, 2-
acetylaminofluorene (2-AAF) and diethylnitrosamine
(DENA) [19-21]. In this study, we injected rats with
DENA, which causes the sequence of fibrosis, cirrhosis
and HCC. By monitoring N-glycomic profiles after
DENA injection, we identified serum N-glycan biomar-
kers that can be used to monitor liver fibrosis, cirrhosis
and HCC. These serum glycan markers were validated
in a rat model in which tumor development is prevented
by using an antitumor drug (S-trans-trans-farnesylthio-
salicyclic acid; FTS).
Results
Alteration of the Profiles of Serum Protein N-glycans
during the development of HCC
We induced liver tumors in Sprague-Dawley rats by
injecting DENA intraperitoneally three times a week for
14 weeks. Starting six weeks after initiation of DENA
treatment, the body weight (BW) of DENA-injected rats
became significantly lower (p < 0.05) than that of con-
trol rats (Figure 1A). Administration of DENA also led
to an increase in serum Tbil, AST, ALT and GGT,
which indicates liver damage (Figure 1B-E). To monitor
tumor development, the rats were sacrificed at different
times during the DENA administration phase.
Figure 1 Body weight and biochemical tests at different time points after DENA administration (weeks). (A) Body weight (g); (B) serum
total bilirubin (TBil, μmol/L); (C) serum alanine aminotransferase (ALT, IU/L); (D) serum aspartate aminotransferase (AST, IU/L); and (E) serum g-
glutamyltransferase (GGT, IU/L). All the values are expressed as mean ± SD on the vertical axis. “Open square” represents the control group and
“slash square” represents the DENA group. Asterisks indicate statistically significant differences between the groups (* p < 0.05, **p < 0.01 and
***p < 0.001).
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Histological examination indicated the evolution of liver
disease caused by hepatotoxicity of DENA (Table 1).
Rats in the DENA group developed mild liver fibrosis
(F1-F2) during week 4 and severe fibrosis (F3) and cir-
rhosis (F4) during week 9. HCC nodules arose from cir-
rhotic livers after 14 weeks of DENA administration. By
week 18, all rats in the DENA group had developed dif-
fusive HCC in cirrhotic livers (Figure 2A).
We analyzed the serum N-glycan profiles in DENA-
treated rats and control rats using DSA-FACE. The
serum desialylated N-glycan profiles (represented as
peaks) gradually changed during progression of HCC in
DENA-treated rats, but they remained unchanged in the
control rats (Figure 2B). We quantified each peak by
normalizing its height to the sum of the heights of all
peaks in the profile, and then we statistically compared
the peaks of control (n = 23), fibrotic (n = 29), cirrhotic
(n = 9) and HCC-bearing (n = 15) rats. The intra- and
inter-assay coefficients of variations (CVs) of the glycan
analysis are less than 5%. All main peaks were altered in
DENA-treated animals compared to controls (Additional
file 1, Figure S1). Peaks R5a and R5b increased gradually
but significantly (p < 0.05) during development of fibro-
sis and HCC in the treated rats (Figure 3), which sug-
gests that R5a and R5b could be used as biomarkers for
monitoring progression of fibrosis and HCC in the
DENA rat model. Interestingly, P1 and P2 gradually
increased in the DENA rats as fibrosis progressed (Addi-
tional file 1, Figure S1). However, their levels were sig-
nificantly lower in HCC rats than in cirrhotic rats. To
distinguish HCC from cirrhosis, we need a marker that
changes only in HCC but not in cirrhosis. Moreover, for
precision and accuracy, a ratio of two variables is better
than the use of a single measurement. We found that
the log of the ratio of R5a to P1 [log(R5a/P1)] and of
R5b to P1 [log(R5b/P1)] were significantly (p < 0.0001)
elevated in HCC rats, but not in cirrhotic, fibrotic and
control animals (Figure 3). In contrast, P5 decreased sig-
nificantly with development of fibrosis and progression
to cirrhosis, but it did not decrease further with devel-
opment of HCC (Figure 3). This indicates that P5 is
associated with progression of fibrosis. On the basis of
these results, we propose the use of the GlycoTest for
monitoring pathology in DENA-treated rats, as depicted
in Figure 4: monitoring fibrosis progression by decreases
in P5 and HCC progression by increases in R5a and
R5b, and detecting HCC by elevation of log(R5a/P1) or
log(R5b/P1).
Evaluation of serum glycan biomarkers after FTS
treatment to prevent HCC
FTS has been shown to act as a functional Ras antago-
nist in cells. It acts mainly by competing with Ras-GTP
for binding to specific binding sites in the plasma mem-
brane, and thereby it prevents active Ras from activating
intracellular downstream signaling pathways [22]. We
previously showed that administration of DENA alone
to rats for over 16 weeks leads to formation of numer-
ous whitish nodules over the surface of the liver and
that the nodules are histologically compatible with HCC
[23]. Treatment of DENA-treated rat with FTS (DNA-
FTS) for 11 weeks prevented formation of nodules and
histological manifestations of HCC [23]. In the present
study, we evaluated our GlycoTest model using glycan
biomarkers in FTS treated DENA rats: FTS prevented
development of cirrhosis, as confirmed macroscopically
and histologically (Figure 5A). N-glycan profiles in sera
from animals treated with DENA (n = 4) or DENA-FTS
(n = 8) were analyzed (Figure 5B). We used the proce-
dure outlined in figure 4 and found that serum values of
P5, R5a and R5b changed towards non-DENA values
after 11 weeks of FTS administration, which indicates
that FTS treatment prevents development of cirrhosis
(Figure 6). Likewise, in rats treated with FTS, the speci-
fic HCC biomarkers log(R5a/P1) and log(R5b/P1)
reverted to levels seen in rats not treated with DENA,
which indicates that FTS prevents formation of HCC
(Figure 6).
Increased level of core-a-1,6-fucosylation during
progression of HCC
The N-glycan structures for the peaks in humans have
been described [16]. Overlay of the rat profiles with
human serum N-glycan profiles revealed that P1
(NGA2F), P2 (NGA2FB), P5 (NA2) and P6 (NA2F)
migrated at the same rates as the corresponding human
Table 1 Histological diagnosis of liver tissue from rats
sacrificed at different time point
DENA
Administration
Group Histological diagnosis (no. animals)
Healthy Fibrosis stage HCC
F1-
2
F3 F4
(cirrhosis)
control 3
week 0 DENA 2
control 3
week 4 DENA 6
control 3
week 6 DENA 12
control 3
week 9 DENA 11 4
control 3
week 14 DENA 5 2
control 6
week 18 DENA 13
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structures during the CE (Additional file 2, Figure S2).
However, peaks R3, R4, R5a and R5b were not found in
human serum, which indicates that N-glycosylation is
somewhat species-specific. This was confirmed by mass
spectrometric glycomics profiling of serum from control
and DENA rats. As shown in Additional file 3, Figure
S3 the rat serum contains some glycans whose antennae
are terminated with alpha galactose moieties. These gly-
cans cannot be biosynthesized in humans [24,25].
We studied the glycan structures using exoglycosi-
dases following by DSA-FACE. We found that the
structures of R5a and R5b were a-1,6-fucosylated, as
they are shifted one residue forward after bovine kid-
ney a-fucosidase digestion, which can remove only one
Figure 2 Representative serum desialylated N-glycan profiles in DENA rats. (A) Liver of untreated control rat (left) and liver of DENA
treated rat showing multifocal HCC nodules. (B) The four panels (from top to bottom) are typical serum N-glycan fingerprints from control,
fibrotic, cirrhotic and HCC rats. Eight major glycan peaks were detected in rat serum, and their patterns in the four rat groups showed
considerable differences. The vertical axis represents the glycan values of the peaks as percent relative fluorescence level. The X-axis represents
the retention time of N-glycans.
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Figure 3 N-glycan values that differ significantly between control, fibrotic, cirrhotic and HCC groups. The vertical axis represents the
glycan values of GycoTest markers R5a, R5b, log(R5a/P1), log(R5b/P1) and P5. Error bars represent 95% confidence intervals for means. Statistical
significance of differences between groups is indicated by the p value.
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a-1,6-fucose from the core N-acetylglucosamine; by
contrast, R3 and R4 were not a-1,6-fucosylated (Figure
7). We did not detect branching a-1,3/4-fucosylated
glycans at significant levels in rat serum because none
of the peaks showed detectable changes after almond
meal a-1,3/4-fucosidase digestion. All serum core-1,6-
fucosylated glycans (peaks 1, 2, R5a, R5b and 6) were
significantly higher in DENA-treated rats than in
untreated rats (see Figure 3 and Additional file 1, Fig-
ure S1). Indeed, serum total core-a-1,6-fucosylated gly-
cans gradually increased in DENA rats during
progression of liver cirrhosis compared to control rats
(Figure 8). This was confirmed by probing western
blots of total serum proteins with lectin of Aspergillus
oryzae (AOL), a specific carbohydrate-binding or car-
bohydrate-crosslinking protein that recognizes a-1,6-
fucosylated glycans [26]. This showed that binding of
serum glycoproteins was considerably increased in rats
with cirrhosis or HCC compared to those with fibrosis
and to control animals.
To determine whether the increase in serum core-
fucosylated glycoproteins was due to their secretion
from the livers during progression of HCC, we probed
blots of liver total proteins with AOL. This showed that
the level of total core fucose residues was higher in the
liver with cirrhosis and HCC than in control tissues
(Figure 9).
Alteration of the expression level of a1,6-
fucosyltransferase (FUT8) in the liver of DENA rats
The terminal glycosylation sequences produced by the
cell are presumed to reflect the expression of the
corresponding glycosyltransferase. Mammalian a1,6-
fucosyltransferase (a1,6FucT), also called FUT8,
Figure 4 A scheme for using the GlycoTest model to monitor progression of HCC in DENA rats. The GlyoTest model includes the
following steps: (1) DENA administration, (2) blood sampling during progression of HCC, (3) serum N-glycan profiling using DSA-FACE, and (4)
analysis of GlycoTest markers. The GlycoTest markers are as follows: a decrease in P5 indicates fibrosis progression; an increase in R5a and R5b
indicates HCC progression; and an elevation of log(R5a/P1) and log(5Rb/P1) points to development of HCC.
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catalyzes the transfer of a fucose residue from GDP-b-
L-fucose, the donor substrate, to the innermost
GlcNAc residue in N-glycan via an a1,6-linkage. To
determine whether alteration of total core fucosylation
in DENA rats was due to alteration of the glycosyla-
tion biosynthesis pathway, real-time PCR was used to
analyze the expression of FUT8 in liver tissue of
DENA-injected rats (HCC group and fibrosis/cirrhosis
group) and non-DENA rats. To our surprise, Fut8
gene expression was much less in DENA rats than in
control rats (Figure 10), which indicates that FUT8 is
not responsible for the high level of core-1,6-fucosyla-
tion in DENA induced HCC.
Discussion
Injection of DENA in rats led to development of cirrho-
sis followed by HCC. N-glycan analysis of rat serum
showed that levels of N-glycans R5a and R5b were posi-
tively correlated with progression of fibrosis and HCC
in DENA rats, whereas P1 (NGA2F) and P2 (NGA2FB)
first increased with severity of fibrosis and then signifi-
cantly dropped after development of HCC. Log(R5a/P1)
and log(R5b/P1) were tumor specific markers that were
significantly elevated in HCC but not in DENA-induced
fibrosis and cirrhosis. Moreover, the value of P5 was
negatively correlated with fibrosis degree, which makes
it a specific marker for progression of liver cirrhosis in
DENA rats. We propose that the GlycoTest model
involving the above-mentioned serum glycan markers
can be used for monitoring the progression of cirrhosis
and HCC in the DENA rat model.
We also evaluated the GlycoTest model in DENA
rats treated with the anticancer drug, FTS. A previous
study demonstrated that administration of DENA leads
to formation of numerous whitish HCC nodules over
the surface of the liver as well as to the development
of cirrhosis, and that FTS treatment prevents both
lesions [23]. As expected, the GlycoTest markers for
cirrhosis and HCC progression (P5, R5a and R5b) in
the FTS treated rats changed towards non-DENA
levels. This change correlated with the prevention of
progression to cirrhosis and HCC that was confirmed
macroscopically and by histology. The GlycoTest for
HCC-specific markers, log(R5a/P1) and log(R5b/P1),
completely reverted to non-DENA levels in the FTS
treated DENA rats, thereby indicating complete pre-
vention of HCC formation. Thus, we demonstrate that
our GlycoTest model can be used as a non-invasive
biomarker for monitoring progression of cirrhosis and
HCC in DENA rats. The GlycoTest model can also be
used to screen drug candidates for protective effects
against HCC.
Increased levels of fucosylation have been reported in
cancer, such as increased core-fucosylation of AFP in
HCC [27,28], and increased fucosylation of haptoglobin
in ovarian, lung, breast and pancreatic cancer [29,30].
Strong expression of a-1,6-FucT was observed in 3′-
MeDAB-induced rat hepatomas and some rat
Figure 5 Desialylated N-glycan profiles of serum proteins from DENA rats treated with FTS. (A) Liver histology after 16 weeks of
treatment with DENA or DENA plus FTS (DENA-FTS). Sirius staining shows that FTS treatment prevented development of cirrhosis. (B) The three
groups of rats were the untreated control (top), DENA plus FTS (DENA-FTS) (middle), and DENA alone (bottom). The vertical axis represents the
glycan values of the peaks as percent relative fluorescence level. The horizontal axis represents the retention time of N-glycans.
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Figure 6 The GlycoTest markers in DENA rats treated with FTS. The levels of GlycoTest markers changed towards non-DENA values after FTS
treatment. Error bars represent 95% confidence intervals for means. Statistical significance of differences between groups is indicated by the p
value.
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hepatoma cell lines [31]. As recently reviewed by
Miyoshi et al. [32], fucosylation is one of the most
important types of sugar modification on glycoproteins
in cancer. In agreement, our lectin blots showed
increased fucosylation of N-glycans on total proteins in
serum and liver in cirrhosis and HCC in the DENA
rats. The total amounts of serum core-fucosylated
structures were increased also during progression of
HCC, partly due to alteration of the core fucosylated
N-glycans of R5a, R5b, P1 (NGA2F), P2 (NGA2FB)
and P 6 (NA2F). As a consequence, P5 (NA2), which
is a precursor for core-fucosylation of biantennary gly-
can, was significantly decreased. N-glycans are synthe-
sized in the ER and Golgi by the sequential addition of
saccharides, such as fucose, by the corresponding gly-
cosyltransferases [33,34]. Changes in the N-glycan pro-
file in serum could be related to changes in the
expression levels of glycosyltransferases in hepatocytes
[33]. Basically, core-fucosylation is regulated by core-
fucosyltransferase (FUT) and the GDP-L-fucose
synthetic pathway. Based on sugar donor specificities,
FUT transfers the substrate of GDP-L-fucose to
the reducing terminal GlcNAc of the core structure of
an asparagine-linked oligosaccharide. GDP-L-fucose
is synthesized through a de novo pathway, a
dominant pathway that involves conversion of cellular
GDP-D-mannose to GDP-L-fucose by GDP-D-mannose-
4,6-dehydratase (GMD) and GDP-4-keto-6-deoxy-D-man-
nose-3,5-epimerase-4-reductase (FX). Noda K et al. [35]
described the relationship between elevated FX expression,
increased production of GDP-L-fucose, and high levels of
fucosylation in human hepatocellular carcinoma and hepa-
toma cell lines. Alpha-1,6-fucosyltransferase (FUT8) is the
only fucosyltransferase involved in core-fucosylation in
mice [36]. However, we did not detect increased expres-
sion of Fut8 gene in DENA rats, which might indicate that
Figure 7 Exoglycosidase sequencing of N-glycans from rat serum glycoproteins. The upper panel shows separation of desialylated rat
serum N-glycans: desialylated N-glycans digested with bovine kidney a-1,6-fucosidase (middle panel) and desialylated N-glycans digested with
almond meal a-1,3-fucosidase (lower panel). Peaks P1, P2, R5a, R5b and P6 contain a-1,6-fucosylated structures. The arrows indicate the changes
in the glycan peaks due to glycosidase digestion that are outlined in the dashed squares. The structures of the N-glycan peaks are shown below
the panels. P1 is an asialo, agalacto, core-a-1,6-fucosylated biantennary glycan (NGA2F). P2 is an asialo, agalacto, core-a-1,6-fucosylated bisected
biantennary (NGA2FB). P5 is an asialo, bigalacto, biantennary glycan (NA2). P6 is an asialo, bigalacto, core-a-1,6-fucosylated biantennary (NA2F).
The symbols used in the structural formulas are the following: “black square” stands for N-acetylglucosamine (GlcNAc); “open circle” stands for
galactose; “grey triangle” stands for a-1,6-linked fucose; “grey circle” stands for mannose.
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another yet unknown alpha-1,6-fucosyltransferase is
involved. The mechanism behind the alteration of fucosy-
lation during HCC development is not fully understood. It
has been reported that overexpression of a-1,6-FucT in
hepatoma cells suppressed intrahepatic metastasis after
splenic injection in athymic mice, partly by a decrease in
the adhesion of core fucosylated a5b1 integrin to fibronec-
tin [37]. Recently, the function of core-fucosylation was
associated with EGFR. The EGF-induced phosphorylation
of EGFR is substantially blocked in Fut8 KO cells, and the
binding of EGF to its receptor (EGFR) requires core fuco-
sylation of N-glycans [38]. Diverse lines of evidence indi-
cate that activation of the TGF-a/EGFR pathway
contributes to HCC formation. It has been reported that
the levels of TGF-a and EGFR mRNA increase at different
stages of cirrhosis and HCC in the DENA rat model, and
that blocking EGFR activity prevents development of HCC
in DENA rats [19]. Increased core-fucosylation in HCC
might be associated with enhanced core-fucosylation of
EGFR, and thus with activation of EGF-induced phosphor-
ylation of the EGFR pathway.
Conclusions
We demonstrate that serum N-glycan markers can be
used to monitor progression of HCC and to evaluate
drugs in the DENA rat model. This GlycoTest model is
particularly important because a rapid non-invasive
diagnostic procedure for tumour progression in this rat
model would greatly facilitate the search for anticancer
drugs. Although the molecular mechanism by which N-
glycosylation is altered in liver disease remains unsolved,
our study confirms that abnormal fucosylation is impor-
tant in HCC development, and that fucosylated glyco-
proteins could be exploited effectively for diagnosis of
HCC in the DENA rat model.
Methods
Experiment design 1
Male Sprague-Dawley rats weighing 180-220 g were pur-
chased from Shanghai SLAC Laboratory Animal Co.,
Ltd. and housed in cages under standard animal labora-
tory conditions in the experimental animal center of the
Second Military Medical University. The rats (n = 60)
were intraperitoneally injected with DENA at 20 mg/kg
body weight three times a week for 14 weeks. The rats
in the control group (n = 24) were injected with an
equivalent volume of physiological saline at the same
times. All animals were kept in a temperature controlled
environment with a 12-h light-dark cycle and had free
access to food and water throughout the study. To
monitor tumor development, the rats were sacrificed at
different times during and after DENA administration.
Blood samples were collected for serum N-glycan analy-
sis and several biochemical liver function tests. Liver tis-
sues were fixed in 10% formalin for histological
examination or frozen in liquid nitrogen and stored at
Figure 8 Total serum core-fucose residues measured by DSA-FACE. Error bars represent 95% confidence intervals for means. Statistical
significance of differences between groups is indicated by the p value.
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-80°C for molecular biological study. All animal care and
experimentation conformed to the guidelines established
by the Second Military Medical University.
Experiment design 2
It has been reported that trans-farnesylthiosalicyclic acid
(FTS) prevents formation of DENA-induced HCC in
rats [23]. Therefore, FTS-treated animals could be used
as a validation group for HCC prevention. In brief, male
Wistar rats (body weight 180-190 g) received weekly
intraperitoneal injections of DENA at 50 mg/kg body
weight for 16 weeks (DENA group). FTS was adminis-
tered intraperitoneally at 5 mg/kg body weight three
times a week starting six weeks after DENA induction
(DENA-FTS group). The animals were sacrificed one
week after the last DENA injection.
Histology
The liver tissues were fixed with 10% formalin,
embedded in paraffin, sectioned, and stained with hema-
toxylin and eosin (HE). Sirius red stain was used to
detect fibrosis. Liver fibrosis was staged histologically by
an experienced hepatopathologist using Scheuer’s classi-
fication, which uses a scale from F0 to F4: F0, no fibro-
sis; F1, enlarged fibrotic portal tracts; F2, periportal or
portal-portal septa, but intact architecture; F3, fibrosis
with architectural distortion, but no obvious cirrhosis;
F4, cirrhosis [39,40].
Figure 9 SDS-PAGE of proteins from serum and liver and western blots probed with AOL. The upper panel shows a western AOL blot of
serum proteins (left) and a gel stained with Coomassie Blue (CBB) of the same serum proteins (right). The lower panel shows a western blot of
liver proteins probed with AOL and b-actin. The lanes are as follows: 1-2: controls; 3-4: cirrhosis; 5-6: HCC. 2+F, 4+F and 6+F are the proteins in
lanes 2, 4 and 6 digested with PNGase F and used as negative controls for AOL binding. The data were reproducible in three independent
experiments.
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Biochemical tests
Routine biochemical tests on sera, including total biliru-
bin (TBil), alanine aminotransferase activity
(ALT), aspartate aminotransferase activity (AST) and
g-glutamyltransferase (GGT), were done using the stan-
dard methods (Hitachi 7600 Analyzer, Hitachi, Japan
Wako Diagnostics reagents, Wako Pure Chemical Indus-
tries Ltd., Japan).
N-glycan profiling using DSA-FACE
N-glycan profiles were generated from 2 μl serum sam-
ples by DSA-FACE technology by using a capillary elec-
trophoresis (CE)-based ABI3130 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA) as pre-
viously described [16,41]. Total N-linked glycans were
released from serum proteins by digestion with peptide
N-glycosidase F (PNGase F) (New England Biolabs, MA,
USA), which cleaves most common mammalian N-
linked oligosaccharides at the N-glycosidic linkage. N-
glycans with reducing ends were derivatized with APTS
(Molecular Probes, Eugene, OR, USA) and directly sepa-
rated using the CE-based DNA sequencer ABI 3130.
Because most serum glycans have a terminal sialic acid,
which contains a negative charge, removal of sialic acid
with hydrolyzing exoglycosidase (a sialidase from
Arthrobacter ureafaciens) (Roche, Indianapolis, IN,
USA) makes the glycan profile much clearer. The
heights of the peaks were measured by GeneMapper
version 3.7 software (Applied Biosystems), and the
height of each peak was converted to a percent of the
total of all peaks.
Structure analysis of N-glycans using exoglycosidase
digestion
One microliter of APTS-labeled desialylated N-glycan
obtained from the DSA-FACE procedure was digested
overnight with various mixtures of exoglycosidases in 10
mM NH4Ac (pH 5.0) at 37°C. The products were then
subjected to electrophoresis on an ABI 3130. The exo-
glycosidases were a-1,3/4-Fucosidase (almond meal)
(Glyko, Novato, CA, USA), which cleaves non-reducing
terminal a-1,3/4-linked fucose, and a-1,6-Fucosidase
(bovine kidney) (Glyko, Novato, CA, USA), which
cleaves non-reducing terminal a-1,6-linked fucose.
MS and MS/MS Analyses of Permethylated Glycans
Approximately 1 μL of rat serum sample was desialy-
lated with hydrolyzing exoglycosidase (a sialidase from
Arthrobacter ureafaciens) (Roche, Indianapolis, IN,
USA). And then desialylated serum was subjected to
reduction, carboxymethylation, and tryptic digestion: the
sample was reduced in 1 ml of 50 mm Tris-HCl buffer,
pH 8.5, containing 2 mg/ml dithiothreitol. Reduction
was performed at 37°C in a water bath for 1 h. Carboxy-
methylation was carried out by the addition of iodoace-
tic acid (5-fold molar excess over dithiothreitol), and the
reaction was allowed to proceed at room temperature in
the dark for 1.5 h. Carboxymethylation was terminated
by dialysis against 4 × 4.5 liters of 50 mm ammonium
bicarbonate, pH 8.5, at 4°C for 48 h. After dialysis,
the sample was lyophilized. The reduced carboxymethy-
lated proteins were then digested with N-p-tosyl-l-
phenylalanine chloromethyl ketone-pretreated bovine
pancreas trypsin (EC 3.4.21.4; Sigma) for 16 h at 37°C in
50 mm ammonium bicarbonate buffer, pH 8.4. The pro-
ducts were purified by C18 Sep-Pak® (Waters) as
described previously [42].
Peptide N-glycosidase F digestion of the tryptic glyco-
peptides was carried out in 50 mM ammonium bicarbo-
nate, pH 8.5, for 20 h at 37°C with 5 units of enzyme
(Roche Applied Science, U.K.). The released N-glycans
were purified from O-glycopeptides and peptides by
chromatography on a Sep-Pak C18 cartridge (Waters
Corp., Milford, MA) and subsequently methylated using
the sodium hydroxide permethylation procedure as
described previously [43].
MALDI-TOF data were acquired on a Voyager-DE
STR mass spectrometer (Applied Biosystems, Foster
City, CA) in the reflectron mode with delayed extrac-
tion. Permethylated samples were dissolved in 10 μl of
70% (v/v) aqueous methanol, and 1 μl of the dissolved
sample was premixed with 1 μl of matrix (20 mg/ml
2,5-dihydroxybenzoic acid in 80% (v/v) aqueous metha-
nol), spotted onto a target plate, and dried under
vacuum.
Further MS/MS analyses of peaks observed in the MS
spectra were carried out using a 4800 MALDI-TOF/
Figure 10 The relative gene expression level of a-1,6-
fucosyltransferase (FUT8) in the liver as measured by Q-PCR.
The horizontal axis represents the experimental groups: control (n =
6), fibrosis (n = 6), cirrhosis (n = 6) and HCC (n = 6). The vertical axis
indicates the expression level of FUT8 relative to the mean of two
housekeeping genes. Statistical significance of differences between
groups is indicated by asterisks: *** p < 0.001.
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TOF (Applied Biosystems) mass spectrometer in positive
ion mode. Signals selected for MS/MS were (M + Na)+
molecular ions.
The collision energy was set to 1 kV, and argon was
used as collision gas. Samples were dissolved in 10 μL
of methanol, and 1 μL was mixed at a 1:1 ratio (v/v)
with 2,5-dihydroxybenzoic acid (20 mg/mL in 70%
methanol in water) as matrix.
The MS and MS/MS data were processed using Data
Explorer 4.9 Software (Applied Biosystems, U.K.). The
mass spectra were baseline corrected (default settings)
and noise filtered (with correction factor of 0.7), and
then converted to ASCII format. The processed spectra
were then subjected to manual assignment and annota-
tion with the aid of a glycobioinformatics tool known as
GlycoWorkBench [44].
Peak picking was done manually, and proposed assign-
ments for the selected peaks were based on molecular
mass composition of the 12C isotope together with
knowledge of the biosynthetic pathways. Sequence ambi-
guities occurring in proposed structures were resolved
by data obtained from MS/MS experiments.
Western lectin blot
A total of 25 μg serum proteins or 50 μg proteins
extracted from frozen liver tissues were separated by
electrophoresis in 10% sodium dodecyl sulfate-polyacry-
lamide gel. The proteins were then transferred to a
nitrocellulose membrane for lectin blot analysis. The
membranes were blocked overnight at 4°C with 3%
bovine serum albumin (BSA) in Tris-buffered saline
(140 mM NaCl, 10 mM Tris-HCl, TBS) and then incu-
bated for 1 h at room temperature with 5 μg/ml of bio-
tinylated Aspergillus oryzae L-fucose-specific lectin
(AOL) (Funakoshi Co., Ltd., Tokyo, Japan) in TBST buf-
fer (TBS containing 0.05% Tween 20). After four washes
of 5 min each with TBST, the membranes were
incubated with 1/1000 diluted horseradish peroxidase-
conjugated Streptavidin (R&D Systems, Minneapolis,
MN, USA) for 1 h at room temperature. The mem-
branes were washed four times again with TBST and
developed with an ECL system (Amersham Biosciences
Inc., Piscataway, NJ, USA).
RNA extraction and real-time RT-PCR
RNA was extracted from frozen liver tissues with Qia-
gen RNeasy mini kit according to the manufacturer’s
instructions (QIAGEN GmbH, Hilden, Germany). The
purity and concentration of RNA were determined by a
Nano Drop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). cDNA was
synthesized starting from 2 μg of total RNA by using
iScript cDNA Synthesis Kit (Bio-Rad Laboratories Inc.,
Hercules, California, USA).
Real-time qPCR using the Light Cycler 480 (Roche
Diagnostics, Vilvoorde, Belgium) was performed on a
16-fold dilution of the cDNA. Each 10-μl assay con-
tained 5 μl of 2× Fast SYBR® Green Master mix
(Applied Biosystems, CA, USA) containing FastStart
Taq DNA Polymerase, reaction buffer, dNTP mix
(with dUTP instead of dTTP), SYBR Green I dye,
MgCl2, 2 μl primer mix for each gene (final concentra-
tion of 0.5 μM each). To normalize the liver sample
data, we used the genes for glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), tyrosine 3-monooxy-
genase/tryptophan 5-monooxygenase activation
protein, and zeta polypeptide (Ywhaz). Each reaction
was performed in triplicate. PCR cycling consisted of
denaturation at 95°C for 5 min followed by 50 cycles
of 95°C for 10 sec, 60°C for 30 sec, and detection for 1
sec at 72°C. The Ct data were analyzed with Excel and
GraphPad Prism 4. Primers were designed using the
Primer Express program (Applied Biosystems). The
sequences are shown in Table 2.
Statistical Analysis
All quantitative variables are presented as mean ± SD.
The unpaired t-test for comparison of two groups was
used, and Welch’s correction was applied if the assump-
tion of equal variance was not accepted. For comparison
of more than two groups, one-way ANOVA was per-
formed. All reported p-values are two-tailed, and
p-values < 0.05 are considered statistically significant.
Statistical analysis was performed with SPSS 15.0 soft-
ware (SPSS, Chicago, IL, USA). The coefficients of varia-
tion (CVs) for peak intensity were averaged in Microsoft
Excel.
Table 2 PCR primer pairs used in the present study
Rattus Norvegicus Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) Amplicon Length (bp)
FUT8 CCATCCTCGGCCTCCTTACT ACTGGGACACCCACCACACT 101
GAPDH ACTCTACCCACGGCAAGTTC TACTCAGCACCAGCATCA 133
Ywhaz AAAAAGGAGATGCAGCCGAC GTTGAGGGCCAGACCCAGT 51
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http://www.molecular-cancer.com/content/9/1/215
Page 13 of 15
Additional material
Additional file 1: Figure S1. Serum N-glycan values in the DENA rats
with fibrosis, cirrhosis and HCC are shown. The vertical axis represents
glycan values of P1, P2, R3, R4 and P6. Error bars represent 95%
confidence intervals for means.
Additional file 2: Figure S2. Serum desialylated N-glycan profiles from
human and rat. The four panels from top to bottom are N-glycan
fingerprint from human serum, N-glycan fingerprint from rat serum, N-
glycan fingerprint from the pool sample of human and rat sera, and
overlay of human and rat (blue curves represent a human profile and
red curves represent rat profile). The vertical axis represents the glycan
values of the peaks as percent relative fluorescence level. The X-axis
represents the retention time of N-glycans.
Additional file 3: Figure S3. Desialylated serum N-glycan structures
were analysed by MALDI-TOF MS and MS/MS. S3-A: Profile of total
permethylated N-glycans in tumor rat serum sample, S3-B: profile of total
permethylated N-glycans in control rat serum. MALDI-MS/MS sequencing
showed that the fucosylated components were mixtures. The majority
are core fucosylated but a minor portion are antenna fucosylated.
Abbreviations
HCC: Hepatocellular carcinoma; DENA: diethylnitrosamine; DSA-FACE: DNA
sequencer-assisted (DSA) and fluorophore-assisted carbohydrate
electrophoresis (FACE); PNGase F: peptide N-glycosidase F; APTS: 8-amino-
1,3,6-pyrenetrisulfonic acid; NA2: bigalacto biantennary glycan; NA2F:
bigalacto core-a-1,6-fucosylated biantennary; FUT: fucosyltransferase; AOL:
Aspergillus oryzae lectin; CBB: Coomassie Brilliant blue; FTS:
farnesylthiosalicyclic acid;
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